| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 Jan 2025 | 27 Dec 2024 |
| NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve The intimation is filed to inform that the Board Meeting of the Company shall be held on Tuesday January 28 2025 for approval of Quarterly Financial Results for the Quarter ended as on December 31 2024. We hereby inform that the Board of Directors (Board) of the Company at its Meeting held today i.e. January 28, 2025 inter-alia have considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024 as recommended by the Audit Committee of the Company. (As Per BSE Announcement Dated on: 28/01/2025) | ||
| Board Meeting | 25 Oct 2024 | 27 Sep 2024 |
| NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve the Unaudited Financial Results for the quarter ended September 30 2024 Filing of the outcome of Board Meeting and Unaudited Financial Results for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 25.10.2024) | ||
| Board Meeting | 29 Jul 2024 | 27 Jun 2024 |
| Intimation in relation to Board meeting and closure of Trading window for period July 01, 2024 to July 31, 2024 Outcome - Unaudited Financial Results for the Quarter ended June 30, 2024 (As Per BSE Announcement dated on 29.07.2024) | ||
| Board Meeting | 28 Jun 2024 | 28 Jun 2024 |
| Board Meeting outcome for meeting of Board of Directors of Novartis India Limited held on June 28, 2024 for appointment of additional Director (designated as Whole Time Director) | ||
| Board Meeting | 10 May 2024 | 27 Mar 2024 |
| NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited Financial Results of the Company for the year ended March 31 2024; and recommend dividend on equity shares of the Company if any for the financial year ended March 31 2024 Final Dividend & Audited Results (As per BSE Bulletin dated on 27/03/2024) Outcome of the Meeting of the Board of Directors of Novartis India Limited (the Company) held on May 10, 2024 Corporate Action - Board approved dividend Corporate Action - fixes book closure (As Per BSE Announcement dated on 10.05.2024) | ||
| Board Meeting | 8 May 2024 | 8 May 2024 |
| The Resolution is passed approving the appointment of Company Secretary and Compliance officer of Novartis India Limited. The Resolution is passed approving the appointment of Company Secretary and Compliance officer of Novartis India Limited. Appointment of Company Secretary and Compliance officer in Novartis India Limited. Approval for the appointment of Company Secretary and Compliance officer by Novartis India Limited. | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
